drugset
Drugs / LY3009120
last change Oct 2018 re-read 3 minutes ago

LY3009120

also known as DP-4978 · Pan-raf inhibitor ly3009120

Small molecule targets ARAF, BRAF, RAF1 via inhibition

Developed for
colorectal neoplasm · melanoma · metastatic neoplasm · non-small cell lung carcinoma
Investigated by
Eli Lilly and Company

Trials 1

today NCT02014116 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02014116 Nov 2013 → Apr 2017 colorectal neoplasm, melanoma, metastatic neoplasm, non-small cell lung carcinoma Eli Lilly and Company Terminated No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2015-04-20 Eli Lilly and Company Results Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 lilly.com ↗

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LY3009120 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02014116 ↗
Known as DP-4978 ChEMBL registry synonym — accepted as the source's own label CHEMBL3577124 ↗
Known as Pan-raf inhibitor ly3009120 ChEMBL registry synonym — accepted as the source's own label CHEMBL3577124 ↗
Action Inhibit “Serine/threonine-protein kinase A-Raf inhibitor” CHEMBL3577124 ↗
2

“Serine/threonine-protein kinase B-raf inhibitor” CHEMBL3577124 ↗

“Serine/threonine-protein kinase RAF inhibitor” CHEMBL3577124 ↗
Modality Small molecule — CHEMBL3577124 ↗
Route Oral “Administered orally.” NCT02014116 ↗
Target ARAF “Serine/threonine-protein kinase A-Raf inhibitor” CHEMBL3577124 ↗
Target BRAF “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL3577124 ↗
Target RAF1 “Serine/threonine-protein kinase RAF inhibitor” CHEMBL3577124 ↗